Product Overview

Daflora M 10/1000 is a combination antidiabetic medication containing Dapagliflozin Propanediol Monohydrate 10 mg and Metformin Hydrochloride IP 1000 mg (Sustained Release), formulated for the effective management of Type 2 Diabetes Mellitus. This dual-action therapy combines the benefits of an SGLT2 inhibitor with a sustained-release biguanide to provide comprehensive blood glucose control through complementary mechanisms of action.

Dapagliflozin promotes the elimination of excess glucose through urine by inhibiting sodium-glucose co-transporter 2 (SGLT2) in the kidneys, while Metformin reduces hepatic glucose production, decreases intestinal glucose absorption, and improves insulin sensitivity. Together, these actions help achieve effective glycemic control while supporting long-term diabetes management.

Daflora M 10/1000 is commonly prescribed alongside a healthy diet and regular physical activity and may be used when monotherapy does not provide adequate blood glucose control. The sustained-release formulation of Metformin offers prolonged therapeutic activity with improved gastrointestinal tolerability and convenient once-daily dosing, helping enhance patient adherence.

Manufactured under stringent pharmaceutical quality standards, Daflora M 10/1000 provides consistent efficacy, safety, and reliability, making it a trusted therapeutic option in modern diabetes care.

How It Works

Dapagliflozin selectively inhibits SGLT2 receptors in the kidneys, reducing glucose reabsorption and increasing urinary glucose excretion. Metformin Hydrochloride works by decreasing glucose production in the liver, improving insulin sensitivity, and reducing intestinal glucose absorption. Together, these complementary mechanisms provide effective blood glucose control while supporting metabolic health and reducing the risk of diabetes-related complications.

Therapeutic Applications

Daflora M 10/1000 may be prescribed for the management of:

• Type 2 Diabetes Mellitus
• Inadequately Controlled Blood Glucose Levels
• Combination Antidiabetic Therapy
• Cardiovascular Risk Reduction in appropriate patients
• Chronic Kidney Disease (CKD) in eligible patients
• Long-term Glycemic Management

Key Benefits

• Dual-action therapy for comprehensive blood glucose control.
• Combines the benefits of Dapagliflozin and Sustained-Release Metformin.
• Helps improve insulin sensitivity and reduce hepatic glucose production.
• Promotes urinary glucose excretion independent of insulin.
• Convenient sustained-release formulation for improved patient compliance.
• Manufactured under stringent pharmaceutical quality standards.

Quality Commitment

Vinix Biopharma is committed to delivering high-quality antidiabetic medicines manufactured under stringent pharmaceutical quality standards. Daflora M 10/1000 undergoes comprehensive quality assurance and rigorous testing to ensure safety, efficacy, consistency, and reliability. Every batch is carefully evaluated to maintain product integrity and support optimal patient care.

Storage Information

Store in a cool, dry place below 30°C. Protect from moisture and direct sunlight. Keep out of reach of children.

Disclaimer

Daflora M 10/1000 should be used only under the supervision of a qualified healthcare professional. Dosage and duration of treatment should be determined by the treating physician based on the patient’s clinical condition, medical history, and therapeutic requirements.